Literature DB >> 7478582

Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins.

M Hall1, S Bates, G Peters.   

Abstract

A number of low molecular weight proteins have recently been identified that specifically inhibit the function of cyclin-dependent protein kinases in mammalian cells. These fall into two distinct families based on primary sequence comparisons and probable modes of action. Using a simple in vitro binding assay, we show that p21CDKN1 and the related p27KIP1 can efficiently interact with cyclins D1, D2, D3, E and A, and to a lesser extent with cyclin B. By generating a deleted form of cyclin D1 that binds to p21 and p27 but not to Cdks, we confirm that these interaction do not depend on stoichiometric amounts of the relevant kinase subunit. Moreover, p21 and p27 do not detectably associated with kinase subunits unless a cyclin is present. This is in sharp contrast to the properties of p16CDKN2 and p15MTS2/INK4b which bind to Cdk4 and Cdk6 in the absence of any cyclin. These data suggest that p21 and p27 act as broad spectrum regulators of cyclin dependent kinase function by participating in ternary complexes whereas the p16 family specifically interfere with the formation of cyclin D-dependent kinase complexes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478582

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  Hepatocyte growth factor releases mink epithelial cells from transforming growth factor beta1-induced growth arrest by restoring Cdk6 expression and cyclin E-associated Cdk2 activity.

Authors:  M Tsubari; J Taipale; E Tiihonen; J Keski-Oja; M Laiho
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

Review 2.  Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products.

Authors:  C Swanton; N Jones
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

Review 3.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

4.  Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.

Authors:  Cong Zhang; Leiguang Ye; Songlei Guan; Shunzi Jin; Weili Wang; Shilong Sun; Kuang-Hui Lee; Jun Wei; Baogang Liu
Journal:  Tumour Biol       Date:  2014-03

5.  Circulating antibodies to p16 protein-derived peptides in breast cancer.

Authors:  Cairen Chen; Yile Huang; Cong Zhang; Tong Liu; H E Zheng; Shuli Wan; Shilong Sun; Qingyong Meng; Yubing Chen; Jun Wei
Journal:  Mol Clin Oncol       Date:  2015-01-14

6.  Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity.

Authors:  R C Jordan; G Bradley; J Slingerland
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

7.  Rapid purification of protein complexes from mammalian cells.

Authors:  D Medina; N Moskowitz; S Khan; S Christopher; J Germino
Journal:  Nucleic Acids Res       Date:  2000-06-15       Impact factor: 16.971

8.  Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase.

Authors:  S Rao; D C Porter; X Chen; T Herliczek; M Lowe; K Keyomarsi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

9.  Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors".

Authors:  Laurence Bockstaele; Hugues Kooken; Frederick Libert; Sabine Paternot; Jacques E Dumont; Yvan de Launoit; Pierre P Roger; Katia Coulonval
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 10.  Aberrant cell cycle regulation in cervical carcinoma.

Authors:  Young Tae Kim; Min Zhao
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.